Modality
Degrader
MOA
BCL-2i
Target
SOS1
Pathway
Wnt
Prostate Ca
Development Pipeline
Preclinical
Feb 2021
→ Jul 2026
PreclinicalCurrent
NCT06541058
206 pts·Prostate Ca
2021-02→2026-07·Recruiting
206 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-07-013mo awayInterim· Prostate Ca
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
Preclinical
Recruit…
Catalysts
Interim
2026-07-01 · 3mo away
Prostate Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06541058 | Preclinical | Prostate Ca | Recruiting | 206 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D |